Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Smaller doses of CagriSema pack a big punch for obesity treatment. The REDEFINE 9 trial found that CagriSema at 1.7 mg and 1 mg doses each drove over 20% body weight reduction in adults with obesity — nearly matching results seen at the higher 2.4 mg dose. With FDA approval expected by end of 2026, patients and providers may soon have more flexible dosing options.
The REDEFINE 9 trial has good news for people who struggle with side effects from higher-dose obesity medications: lower doses of CagriSema (cagrilintide/semaglutide) work just as well. Presented at ObesityWeek and published in The Lancet Diabetes & Endocrinology, the trial showed that both the 1.7 mg and 1 mg doses of the combination drug led to more than 20% body weight reduction in adults with obesity — compared to just 2% in the placebo group.
This is notable because the most-studied dose has been 2.4 mg each, and these lower doses appear to deliver comparable efficacy. Researchers say this could give clinicians and patients more flexibility — especially for those who experience gastrointestinal side effects at higher doses. CagriSema is not yet FDA-approved, but a decision on its obesity indication is expected before the end of 2026.
By the Numbers:
Why it matters: If approved, having multiple effective dose options for CagriSema could make obesity treatment more accessible and tolerable — allowing providers to tailor therapy to individual patient needs rather than defaulting to a one-size-fits-all approach.